Clinical trials: Malignant Neoplasm of Lung
Recurrent Respiratory Papillomatosis, Pulmonary Neoplasm
The Natural History and Biological Study of Pulmonary Recurrent Respiratory Papillomatosis (pRRP)
Recurrent respiratory papillomatosis (RRP) is an orphan disease that affects approximately 20,000 people in the United States and is caused by infection with human papillomavirus (HPV) types 6 and 11.
- Trial name
- NCT06412172
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Massachusetts General Hospital
Lung Cancer, Prostate Cancer
Enbrel Versus Placebo With Radiation Therapy to Combat Fatigue and Cachexia
Patients who receive radiation therapy often have fatigue or a decrease in feeling well causing a "wasting" away. For patients with advanced disease of lung cancer, prostate cancer, or cancer that has spread to the bone, it is…
- Conditions
- Lung Cancer, Prostate Cancer, Neoplasm Metastasis, Bone Cancer
- Trial name
- NCT00127387
- Testing
- Enbrel
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Malignant Solid Tumor
A Drug-Interaction Study of Necitumumab (IMC-11F8) in Combination With Gemcitabine-Cisplatin
The purpose of this study is to investigate the pharmacokinetics (PK) of necitumumab in combination with gemcitabine-cisplatin in participants with advanced malignant solid tumors and to assess the potential for drug-drug…
- Trial name
- NCT01606748
- Testing
- Necitumumab, Gemcitabine, Cisplatin
- Where
- 4 sites in United States
- Volunteers
- 35 people
- Sponsor
- Eli Lilly and Company
Solid Tumor, Small Cell and Non-small Cell Lung Cancer
RAPA-201 Therapy of Solid Tumors
The therapy of solid tumors has been revolutionized by immune therapy, in particular, approaches that activate immune T cells in a polyclonal manner through blockade of checkpoint pathways such as PD-1 by administration of…
- Conditions
- Solid Tumor, Small Cell and Non-small Cell Lung Cancer, Head and Neck Cancer, Squamous Cell Carcinoma of Oral Cavity
- Trial name
- NCT05144698
- Testing
- RAPA-201 Rapamycin Resistant T Cells, Chemotherapy Prior to RAPA-201 Therapy, Pembrolizumab (PD-1 Blocking Antibody)
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Rapa Therapeutics LLC
Non Small Cell Lung Cancer, Non-squamous Non-small-cell Lung Cancer
Cabozantinib With Pemetrexed in Advanced Non-small Cell Lung Cancer, Urothelial Cancer and Malignant Mesothelioma
This study will combine cabozantinib with pemetrexed to treat patients with non-small cell lung cancer, urothelial cancer and advanced malignant mesothelioma.
- Conditions
- Non Small Cell Lung Cancer, Non-squamous Non-small-cell Lung Cancer, Urothelial Carcinoma, Malignant Mesothelioma
- Trial name
- NCT04173338
- Testing
- Cabozantinib, Pemetrexed
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Augusta University
Bronchial Neoplasm Benign
Survivin and Fibulin-3 in Benign and Malignant Respiratory Diseases
Purpose: Survivin is a common member of the inhibitors of the apoptosis protein (IAP) family with a dual role in promoting cell proliferation and preventing apoptosis.
- Trial name
- NCT04413292
- Testing
- ELISA assays and Westren blot analysis of survivin and fibulin-3 expression
- Volunteers
- 93 people, healthy volunteers welcome
- Sponsor
- South Valley University
Lung Cancer
The Lung PCA: A Multi-Dimensional Atlas of Pulmonary Premalignancy
This protocol pertains specifically to the prospective lung squamous cell carcinoma pre-malignant lesion (PML) cohort that will form a primary study group for the Lung Pre-Cancer Atlas.
- Trial name
- NCT03881098
- Testing
- Bronchoscopies, Sputum Sample, Venipuncture
- Where
- 2 sites in United States
- Volunteers
- 240 people
- Sponsor
- University of Colorado, Denver
Lung Cancer (Diagnosis), Chronic Obstructive Pulmonary Disease (COPD)
Muco-active Agent Use and Clinical Outcomes After Lung Cancer Diagnosis in Chronic Obstructive Pulmonary Disease
The Target Trial Emulation of Muco-active Agent Use and Clinical Outcomes After Lung Cancer Diagnosis Among Patients With Chronic Obstructive Pulmonary Disease (TAME-CLC) study is a retrospective observational cohort study using…
- Trial name
- TAME-CLC (NCT07712016)
- Testing
- Muco-active agents, No muco-active agent use
- Where
- 2 sites in South Korea
- Volunteers
- 27,000 people
- Sponsor
- Seoul National University
Metastatic Non Small Cell Lung Cancer, Advanced Non Small Cell Lung Cancer
Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation
This Phase 3 study will evaluate the efficacy of the investigational agent MRTX849 (adagrasib) versus docetaxel in patients who have been previously treated for metastatic NSCLC with a KRAS G12C mutation.
- Trial name
- KRYSTAL-12 (NCT04685135)
- Testing
- MRTX849, Docetaxel
- Where
- 380 sites in United States, Australia and 22 more
- Volunteers
- 453 people
- Sponsor
- Mirati Therapeutics Inc.
Breast Neoplasms, Carcinoma, Non-Small-Cell Lung
A Phase I Study of [68Ga]Ga-DWJ155 in Patients With Breast and Lung Cancers
This is a phase I, open label first in human study to evaluate the imaging performance, safety, biodistribution and pharmacokinetics of [68Ga]Ga-DWJ155 in patients ≥ 18 years of age with hormone receptor positive/HER2 negative…
- Trial name
- NCT07117214
- Testing
- [68Ga]Ga-DWJ155
- Where
- Netherlands
- Volunteers
- 36 people
- Sponsor
- Novartis Pharmaceuticals
CD30-Positive Neoplastic Cells Present, Malignant Mesothelioma
Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery
This phase II trial studies how well brentuximab vedotin works in treating patients with CD30 positive (+) malignant mesothelioma that cannot be removed by surgery.
- Trial name
- NCT03007030
- Testing
- Brentuximab Vedotin, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- M.D. Anderson Cancer Center
Ultracentral Pulmonary Tumors, Lung Cancer (T1 N0 M0 and T2 N0 M0)
Multicentre Phase II Trial Evaluating Stereotactic Body Radiotherapy on Ultra-central Lung Tumors on MR-Linac
Phase II multicenter trial evaluating the safety, tolerability, and feasibility of MRI-guided stereotactic radiotherapy using MRI-LINAC in patients with ultracentral lung tumors or lymphadenopathy in the context of controlled…
- Conditions
- Ultracentral Pulmonary Tumors, Lung Cancer (T1 N0 M0 and T2 N0 M0), Mediastinal Lymph Node Recurrence From All Types of Primary Cancer, Pulmonary Node Recurrence From All Types of Primary Cancer
- Trial name
- LIN-LUNG-2504 (NCT07733219)
- Testing
- MRI-LINAC radiotherapy
- Volunteers
- 59 people
- Sponsor
- Centre Oscar Lambret
Medullary Thyroid Cancer, Infantile Myofibromatosis
A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors
This is an open-label, multi-center Phase 1/2 study of oral LOXO-292 in pediatric participants with an activating rearranged during transfection (RET) alteration and an advanced solid or primary CNS tumor.
- Conditions
- Medullary Thyroid Cancer, Infantile Myofibromatosis, Infantile Fibrosarcoma, Papillary Thyroid Cancer
- Trial name
- LIBRETTO-121 (NCT03899792)
- Testing
- Selpercatinib
- Where
- 26 sites in United States, Australia and 9 more
- Volunteers
- 36 people
- Sponsor
- Eli Lilly and Company
Epithelioid Mesothelioma, Recurrent Malignant Mesothelioma
Tivantinib in Treating Patients With Previously Treated Malignant Mesothelioma
This phase II trial studies how well tivantinib works in treating patients with previously treated malignant mesothelioma. Tivantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
- Conditions
- Epithelioid Mesothelioma, Recurrent Malignant Mesothelioma, Sarcomatoid Mesothelioma, Stage II Pleural Mesothelioma
- Trial name
- NCT01861301
- Testing
- Laboratory Biomarker Analysis, Tivantinib
- Where
- 18 sites in United States
- Volunteers
- 18 people
- Sponsor
- National Cancer Institute (NCI)
Hypereosinophilic Syndrome, Systemic Mastocytosis
Imatinib Mesylate in Patients With Various Types of Malignancies Involving Activated Tyrosine Kinase Enzymes
This trial is for various types of malignancies which may depend on certain enzymes (tyrosine kinases) for growth. The objective of this study is to assess to what extent imatinib mesylate blocks these enzymes and to assess the…
- Conditions
- Hypereosinophilic Syndrome, Systemic Mastocytosis, Chronic Myelomonocytic Leukemia, Dermatofibrosarcoma
- Trial name
- NCT00171912
- Testing
- imatinib mesylate
- Where
- Australia
- Volunteers
- 38 people
- Sponsor
- Novartis Pharmaceuticals
Non Small Cell Lung Cancer, Metastatic
Bortezomib in Combination With Gemcitabine and Cisplatin in Advanced or Metastatic Non-Small Cell Lung Cancer
The primary objective of this study is to establish the objective response rate (complete response + partial response) following treatment with VELCADE in combination with cisplatin plus gemcitabine in patients with locally…
- Trial name
- NCT01633645
- Testing
- Bortezomib, Gemcitabine, Cisplatin
- Where
- 5 sites in Greece
- Volunteers
- 53 people
- Sponsor
- University Hospital of Crete
Carcinoma, Small Cell
Study of Radiation Dose Intensity Concurrent With Chemotherapy For Limited Stage Small Cell Lung Cancer
Patients who have limited stage small cell lung cancer are presently treated with chemotherapy and radiation therapy (RT). Despite this aggressive treatment the vast majority of patients will have their cancer recur after…
- Trial name
- NCT00126828
- Testing
- External beam radiotherapy
- Where
- Canada
- Volunteers
- 18 people
- Sponsor
- AHS Cancer Control Alberta
Advanced Biliary Tract Carcinoma, Advanced Colorectal Carcinoma
CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors
This phase II trial tests how well CPI-613 (devimistat) in combination with hydroxychloroquine (HCQ) and 5-fluorouracil (5-FU) or gemcitabine works in patients with solid tumors that may have spread from where they first started…
- Conditions
- Advanced Biliary Tract Carcinoma, Advanced Colorectal Carcinoma, Advanced Gastroesophageal Junction Adenocarcinoma, Advanced Lung Adenocarcinoma
- Trial name
- NCT05733000
- Testing
- Biospecimen Collection, Computed Tomography, Devimistat
- Where
- United States
- Volunteers
- 94 people
- Sponsor
- Northwestern University
Thymus Tumors, Adoptive Cellular Therapy
Rapid Autopsy and Procurement of Cancer Tissue
Background: Individuals with cancer of the lung, chest cavity, ovary, or bladder, as well as patients who have been treated with adoptive cell therapy unfortunately commonly succumb to their disease.
- Conditions
- Thymus Tumors, Adoptive Cellular Therapy, Mesothelioma, Genitourinary Cancers
- Trial name
- NCT01851395
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Malignant Neoplasm in the Brain, Recurrent Non-Small Cell Lung Carcinoma
Radiation Therapy and Stereotactic Radiosurgery With or Without Temozolomide or Erlotinib in Treating Patients With Brain Metastases Secondary to Non-Small Cell Lung Cancer
This randomized phase III trial is studying whole-brain radiation therapy and stereotactic radiosurgery with or without temozolomide or erlotinib to see how well they work compared to whole-brain radiation therapy and…
- Conditions
- Metastatic Malignant Neoplasm in the Brain, Recurrent Non-Small Cell Lung Carcinoma, Stage IV Non-Small Cell Lung Cancer AJCC v7
- Trial name
- NCT00096265
- Testing
- 3-Dimensional Conformal Radiation Therapy, Erlotinib Hydrochloride, Stereotactic Radiosurgery
- Where
- 83 sites in United States, Canada
- Volunteers
- 126 people
- Sponsor
- National Cancer Institute (NCI)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.